Abeona Therapeutics (ABEO) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
8 Jul, 2026Executive summary
Significant progress made in addressing FDA's Complete Response Letter (CRL) for pz-cel BLA, with nearly all CMC issues resolved and only two validation items outstanding; no new clinical trials or data requested by FDA.
BLA resubmission for pz-cel is on track for the second half of 2024, following a successful Type A meeting with FDA; commercial launch preparations, including cGMP facility readiness, site onboarding, and payer engagement, are advancing.
Entered a non-exclusive agreement with Beacon Therapeutics for AAV204 capsid evaluation in ophthalmology gene therapies.
Preclinical pipeline includes AAV-based gene therapies for genetic eye diseases, with pre-IND meetings completed.
Completed a $75 million underwritten offering in May 2024, strengthening the balance sheet and extending cash runway.
Financial highlights
Cash, cash equivalents, short-term investments, and restricted cash totaled $123 million as of June 30, 2024, up from $62.7 million at March 31, 2024.
Net income for Q2 2024 was $7.4 million, including a $24.9 million gain from warrant liability remeasurement, compared to a net loss of $16.7 million in Q2 2023.
Research and development expenses were $9.2 million for Q2 2024, up from $8.5 million in Q2 2023; general and administrative expenses rose to $8.6 million from $5 million, mainly due to commercial and launch preparation.
Net cash used in operating activities was $12.7 million for Q2 2024.
Total revenue was nil for Q2 2024, compared to $3.5 million in Q2 2023, due to absence of milestone payments.
Outlook and guidance
Sufficient financial resources, including a $50 million credit facility, are expected to fund operations into 2026, excluding potential pz-cel revenue or PRV proceeds.
BLA resubmission for pz-cel is expected in the second half of 2024; FDA review anticipated to take six months if accepted.
Commercial launch of pz-cel targeted approximately three months after potential approval.
Continued investment in commercialization and R&D expected to result in ongoing operating losses for the foreseeable future.
Latest events from Abeona Therapeutics
- A 12.49 million-share resale shelf follows the ABO-801 acquisition and $30 million private placement.ABEO
Registration filing - ZEVASKYN launch ramp leads, with ABO-801 and partnered-program catalysts ahead.ABEO
Jefferies Global Healthcare Conference - ABO-801 adds a redesigned EoE Phase III program alongside ZEVASKYN’s expanding launch.ABEO
Stifel 2026 Healthcare Conference 2026 - Strong histologic results; exploratory DSQ mapping informs symptom endpoint strategy.ABEO
Clinical Development History presentation - ZEVASKYN’s $11.4M Q2 revenue anchors a broader cell- and gene-therapy pipeline.ABEO
Corporate presentation - ZEVASKYN revenue rose 18% QoQ as ABO-801 advanced toward Phase III.ABEO
Q3 2026 - ZEVASKYN launch accelerates with rising revenue, broad access, and a robust pipeline of gene therapies.ABEO
H.C. Wainwright 28th Annual Global Investment Conference - Durable gene therapy launch advances with expanding treatment centers and strong patient access.ABEO
Morgan Stanley 24th Annual Global Healthcare Conference - Steady ZEVASKYN rollout, robust coverage, and pipeline advances set stage for strong future growth.ABEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 ZEVASKYN revenue up 31% to $11.4M, NTAP status secured, net loss $20.2M, cash $146.8M.ABEO
Q2 2026